Krystexxa 8 mg/50mL
pegloticase · INJECTION, SOLUTION · Horizon Therapeutics USA, Inc.
No Recall History
Plain English
Krystexxa is a injection, solution containing pegloticase at 8 mg/50mL, taken intravenous. Manufactured by Horizon Therapeutics USA, Inc..
Key Facts
- Brand Name
- Krystexxa
- Generic Name
- pegloticase
- NDC Code (Product)
75987-058- Manufacturer
- Horizon Therapeutics USA, Inc.
- Strength
- 8 mg/50mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA125293
- Drug Class
- Uric Acid-specific Enzyme [EPC]
- Marketing Start
- 08/29/2025
Recall History
No Recall HistoryFrequently Asked Questions
What is Krystexxa used for?
Krystexxa contains pegloticase. It is a injection, solution taken intravenous. Consult your doctor for specific uses.
Is Krystexxa a controlled substance?
Krystexxa is not classified as a controlled substance by the DEA.
What is the generic name for Krystexxa?
The generic name for Krystexxa is pegloticase. There are no other listed brand versions of pegloticase.
What is the NDC code for Krystexxa 8 mg/50mL?
The NDC (National Drug Code) for Krystexxa 8 mg/50mL is 75987-058, listed by Horizon Therapeutics USA, Inc..
Other Krystexxa Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)